Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Things should really get cooking when market volumes reach 5-10M a day!
Early Trading volume today already at 77% of 10 day moving average! Now that the 10Qs are out and stop and yield signs have been removed I expect we’ll see trading grow back into multiple million shares per day, that will likely shatter current PPS resistance.
PPS likely .05 or greater? 10Q indicates per share price return around .05 , at least this is what I got from reading the materials.
Looking at the FDA process charts the fastest we could get through phase 2 is several months to 2 years . Likely still a few years away from market if that is the only formula OncBioMune follows, however, there are some wild cards to getting to market sooner that are other possibilities, as I see them:
1. Right to try legislation, may allow early adoption.
2. Getting an FDA Breakthrough Therapy Designation for the vaccine. (Approval of drugs that provide a substantial improvement over what is currently available to treat a serious disease or condition)
3. FDA expedited Access pathway. The Expedited Access Pathway (EAP) program is a voluntary program for certain medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), premarket notification (510[k]) or requests for De Novo designation.
( this has been mentioned by the company, that it is pursuing)
FDA approved clinical trail it is part of the process. Not second guessing this one. As mentioned in the company PR “all requisite approvals have been granted”. I am certain from DD this refers to FDA requirements and approvals. See the FDA link below it lays it out very well.
The Drug Development Process > Step 3: Clinical Research
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm
Great news I almost stopped reading the board for that reason!! Good insights, relevant posts, and DDs what I want to see. Thanks much!
HHS Supplemental Standards of Ethical Conduct formally defines SRO as “an organization for which the sales of products regulated by the Food and Drug Administration (FDA) constitute ten percent or more of annual gross sales in the organization's previous fiscal year; where an organization does not have a record of sales of FDA-regulated products, it will be deemed to be significantly regulated if its operations are predominately in fields regulated by FDA, or if its research, development, or other business activities are reasonably expected to result in the development of products that are regulated by FDA."
Does the new approved “Right to Try” legislation bring in some revenue early for the vaccine? Interesting thought. I ask OBMP on FB Friday, waiting for their response.
10K discontinuation of México businesses, from reading the material my sense is that it will save the company significant operating and salary losses to the tune of .04 to .16 per share. That’s a big deal translating to the market price of the stock for 2018 just add that to today’s close price of .0349 and you get an adjusted range of .0749 to .1949 PPS.
Easy money on the table to pick up. Getting rid of the México ops & biz was the right move for shareholders. Now let’s see when the market PPS adjustment happens :)
Volume could be a lot heavier if the folks in Fidelity or others could trade (I.e. buy) that explains the large gaps I seen between buy offer and asks. But due to the delinquent 10-Q filing, buying has been put to a stop on many online investment platforms. Just take a look at https://www.otcmarkets.com/stock/OBMP/quote. You’ll see a “Stop Sign” and warning note. I am it sure the trades that have happened since Tuesday 5/22 are not necessarily representative of the market. I certainly hope so, but won’t know for sure until they catch up on their SEC filing and are open to all for buying. I’m long on $OBMP & heavily invested. Will buy more when it is open again.
I got a sense of urgency from him in getting it done as soon as possible, and they were working hard to get it done. I informed him that Fidelity has stopped all buys, waiting for release, but he said it was still trading. I am locked out from buying anymore shares currently and all my limit orders were canceled, waiting public 10-Q release. I heard earlier on this board that Ameritrade is still buy letting orders go through, all Fidelity will let through are sell orders.
Anyone else having trading issues? I cannot trade on Fidelity due to late 10-Q exceeding 5 calendar days. I spoke with Dr Head this morning snd he said the delay is due to pulling all the Mexico business together a bit more complicated. They are working it to get it out soon. He said the stock is trading, I know it’s not a Fidelity, anyone else having any luck?
Interesting that 3M options given on 5/9/2018 with an expiration on same day (5/9/2018) that’s just weird. So they’d have to used the same day, wonder if this is a typo. 3M options cost $40,500 @ $ .0135 strike price. Given nothing happened that day this filing appears to be just some clean up documentation.
The PPS high on 5/9/18 was $ .0140 but the open and close this day was $.0135, volume that day was 812,114, not even close. I am thinking nothing happened, and means nothing to anyone, other than a tidy up of reporting docs.
5 calendar days according to the late filing paperwork and SEC regulations
Notification of 10-Q late filing was submitted on 5-16-2018 the SEC requires the filing on or before the fifth calendar day of the filing.
So doing the math it was due yesterday 5-21-18. I called and left several investor inquiry messages with the company. Waiting for response......
I am thinking it will come out soon otherwise no one will be able to trade stocks.
This is the warning below that went up today. Quick corrective action is required to get reporting out. Is the delay freeze due to buy out talks hmmm? Something is up!
“Warning! This company may not be making material information publicly available
Buying or selling this security on the basis of material nonpublic material information is prohibited under Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b5-1 thereunder. Violators may be subject to civil and criminal penalties”
I would think this has become job 1 today at the company.
Looks like until the 10Q comes out Fidelity has stopped buy orders. I.e. “public information release needed”. I don’t know about the others but that explains the low volume and sluggishness. A bit of punishment for late reporting.
If you are a Fidelity client this is the you get. In addition to all open order limits canceled you placed.
(TC9052) Opening transactions for Pink Sheets (without information) are not permitted because of the risks associated with these securities and all Microcap securities.
IT’s a little more complicated depending on the industry and sectors. Here’s a good read that should help you answer yes or no. https://www.thebalance.com/using-price-to-earnings-356427
Video interview of InMed president following ringing opening bell at TSX
https://newsletter.adnetcms.com/l/u2cVQcu1hNMDKetpN4dmQg/Ps3dSB7cwmpnE8ACciXxEQ/yl7892AlbVCw4763yxjhagS8MA
I see a lot of positive possibilities here, and consistency in direction.
Holding long. Key take away clinical trails to be within a year likely sooner.
4/7/2017 the 52week High was .30/share. My guess without some more interesting news could go to .05-.09 given the 3/6/18 Gardner Insights report showing them as a major player in prostate immunization drug development. The More key investors gradually pick the this information up that level not unreasonable but that’s my best cloudy crystal ball guess.
Taking the emotion out the discussions. I am loading up on $OBMP when can and being patient. After doing D&D this is why I believe the SP is a steal at anything below .10 and bargain basement right now. Albeit you’ll have to wait for the fruit to ripen before harvest.
Key D&D points
1. 4+ patents
2. Successful phase 1a, FDA allowed them to skip 1b go straight to phase 2.
3. Phase 2 plan discussed in 2016 meeting during phase 1 progress presentation. $OBMP Is tracking according to plan and the players laid out 2 years ago. Harvard Medical, UCNT etc. Clearly well throughout executions
4. In 2016, 10.1 Million share purchase agreement to fund phase 2 by Lincoln Capital already In place.
5. Working with FDA to get accelerated pathways to market (breakthrough therapy, Orphan Drug and fast track) for ProscaVax
6. Gardner insights Research 3/6/18 Prostate Specific Antigen Market Study showing $OBMP as one of the major players in this market.
7. In the pipeline after ProscaVax is immunization drug targeting ovarian cancer $$$$
8. $45 billion market size and growing in size to over $119B
9. Big Pharma also chasing solutions as well, and $OBMP owns unique patents and showing great success so far.
So I think with successful phase 2, it’ll go quickly to Phase 3 one of the most expensive but the most important phase where from here it goes for FDA approval. Given their proactivity preparing for phase 2, two years in advance, I would not be surprised if they were already in discussions with them FDA getting this laid out as well.
I believe with successful phase 2 you’ll see tremendous increases in SP continuing through phase 3 to market.
At least that’s my 2 cents. Hope you find this information useful.
Eco Pen shipment info according to MyDx web site: “Estimated Shipping Date: March 31, 2018 - June 30, 2018”
3 month window for release. They are taking preorders online I would be curious what their preorder levels are so far, to get an indication of the product ramp.
It likely would help if TSX or INMED updated news about the company to help new investors. Latest news is 2008 followed by 2005. I still see great things ahead just some growing pains with the new listing. They needed a listing PR blitz / announcement on the TSX with news update. Hopefully they correct this soon.
I do not foresee a return to $1.00 at least for very long. Just think about the statements that were made “ TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline.”
The key here company expects to satisfy conditions in advance of the deadline! I believe it’ll list early and likely go to $5+ on the TSX as new investors and analyst come online.
I see no reason in the next year once trials complete that the SP would not match pretty closely with GWPH and exceed them with the upsides the company brings to bear as multiple products come out of the pipeline.
Just me "Average Joe" investor did a bit of D&D on the company. My opinion is PPS appears to be undervalued I would expect a .02 to .05 range within the quarter....but depends....
The likely reason PPS is lower now is they are experiencing some growing pains and addressing them and QC issues. This affects overall profitability, tooling costs etc. I spent a very long time in manufacturing and production and these issues are typical. It appears the tech is solid and product will continue to ramp & further cost reductions will occur. That's just the way tech works. But they have to be very agile as well with new product tech, it usually only takes competitors 9-12 months for competitors to catch up so they'll need to keep pressing the boundaries of product upgrades of what's possible, as well as do a exceptional job marketing product, showing the value and getting 3rd party reviews and comparisons.
I also took a look at Amazon reviews from purchasers who seemed satisfied with the product giving it an overall rating of 4+. Seems to me PPS will adjust upward with Q2 financials if no big hiccups occur. I would guess a increased PPS i.e. "Moon shot" will come as production ramps, components are standardized and sensor costs are lowered In manufacturing. This is an ongoing process of continuous improvement and in my opinion they have gotten through Version 1.0 early product release and are moving on toward full production. I am not expecting to make millions of $$ overnight but being patient it will happen as profitability increases. An analogy- Kinda like casting my fishing line in waiting for the big fish to bite, don't expect it to happen right away, those not patient may spend allot on bait and moving around frequently to other fishing spots. By the time they come back chances are good you've caught the limit if you've done your job finding the right spot.
Info about version 2.0 below. I know it's from May but still relative to company direction. Current reviews don't indicate what version is being tested would be great to see a comparison.
MyDx Releases MYDX 2.0 with an Array of Advancements as Chemical Analyzers Sold-Out in Q1 and Confirms Delivery of 1,000 Units
New Upgrades Further Address the Potentially False and Misleading Advertising and Labeling in the Cannabis Industry
SAN DIEGO, CA -- (Marketwired) -- 05/16/17 -- MyDx, Inc. (OTCQB: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for the Cannabis professional and retail consumer to correlate the chemical profile of cannabis with its therapeutic effect, today announces a suite of upgrades to its MyDx 1.0 chemical analyzer hardware and software. These upgrades will greatly advance existing capabilities, including improvement in the overall performance of the device and for the first time, will allow the first of three anticipated upcoming sensor releases in AeroDx, which will measure key air quality parameters for cannabis and non-cannabis consumers, to be interchanged seamlessly with the CannaDx Sensors.
MyDx Takes Back-Orders in Q1 on Greater than Expected Demand
MyDx sold out of inventory in Q1 on greater than expected demand for its chemical analyzers and subsequently ordered 1,000 units retrofitted with the newest 2.0 version upgrades. The new units have approximately 200 components to its bill of materials and are currently undergoing final assembly/QA/QC in its production facility in California. The units will be able to accommodate multiple sensors and advances the device to the next- generation of testing capabilities. Q1 Sales combined with back-orders and customer deposits outperformed the same period in the previous year and the company looks forward to fulfilling greater demand for its products.
MyDx is the Official Handheld Chemical Analyzer to the Cannabis Industry by MassRoots
Cannabis users have no idea of what they're buying or consuming because of the lack of enforcement of standardized industry protocols that have diluted QA/QC in the industry. This represents a serious public safety issue and it could be interpreted that the industry is engaged in false and misleading advertising.
To simplify the current public safety issue that exists, consider the following example. If your intent is to replace Xanax with a certain cannabis chemical profile to alleviate Anxiety, then in order to confirm that "prescription" a MyDx device is needed to ensure you're getting the appropriate chemical mix and dosage.
To highlight this further, if a doctor prescribes a 0.5mg dose of Xanax and without proper labeling and tracking, you were sold 25mg of Xanax, this would be a serious public health and safety hazard. And this is exactly the current state of affairs in the cannabis industry where having a MyDx device can provide a higher level of assurance of what you're consuming.
MyDx is an efficient and affordable way to close the transparency gap in the cannabis industry by informing and empowering commercial and retail users to confirm what they're selling, purchasing or consuming and to track how consumers respond to certain chemical profiles to develop more personal therapies for alleviating their ailments.
MyDx to Launch AeroDx Sensors and Associated Mobile App 4.0
AeroDx Sensors are not only expected to detect air quality in its surroundings using the MyDx 2.0 device, but to also ensure air quality and control in cannabis growth facilities as well offer a test for residual solvents in cannabis oils.
AeroDx Sensors are the first of three anticipated sensors to be launched into the market and represents the first versatile sensor to be used with the MyDx Analyzer with applications beyond cannabis. Once AeroDx Sensors are inserted into the MyDx Device, the device becomes an air quality tester with the ability to detect Volatile Organic Compounds (VOC's) such as Formaldehyde, Butane, Toluene, Methane, Benzene and other harmful chemicals, such as Carbon Dioxide, present in the air. It can also monitor temperature and humidity, which can aid in preventing mold and germ growth.
Hardware and Firmware Upgrades
New MyDx 2.0 handheld devices will be retrofitted with new hardware and firmware upgrades to allow for new sensors to be interchanged seamlessly with the CannaDx Sensor. Existing customers under the MyDx Care plan can send their units into MyDx to be upgraded free of charge. The interchangeability of the MyDx upcoming sensors in the device provides a level of testing versatility.
Data, Software and Algorithm Upgrades with Greater CBD Specificity
MyDx has advanced its data accumulation and analytics capabilities by increasing the size and quality of its database and enhancing related software and analytics algorithms. The net result is improved overall device and mobile app performance as well as greater accuracy of CBD value detection among high CBD strains.
Bloomberg's Cannabis round-up mentions InMed in their $5.6B Bio-pharma index IN.c IMLFF bloom.bg/2oPiA1m
My opinion PPS about to pop above $1 by next Tuesday once info disseminates down. When you look at the other competitor company charts on Bloomberg no brainer IMLFF will be on the move!
Revenues soared to $808k, up 110+% year over year, on robust product & licensing sales
For those of you who may have not seen this here is some DD on earning! Enjoy
MyDx Announces Fiscal Year 2016 Results
BY Market Wire
— 9:20 AM ET 04/18/2017
SAN DIEGO, CA -- (Marketwired) -- 04/18/17 -- MyDx, Inc. ( MYDX) a rapidly growing science and technology company that has developed MyDx ( MYDX )®, the first multi-use handheld chemical analyzer for consumers, announces its 2016 fiscal year earnings results and management analysis.
Revenues soared to $808k, up 110+% year over year, on robust product & licensing sales
Product revenue was lifted by increasing demand for CannaDx™ Sensor, which in turn was brought on by greater consumer awareness of MyDx ( MYDX) Products and services.
• Newly created licensing revenue stream topped off year end results as the company developed ways to monetize its extensive proprietary data
• Gross Profit increased by 131% year over year due to the development of additional revenue streams with more favorable profit margins
• Licensing revenues and AquaDx® and OrganDx® disposable sensors have a lower variable cost base, which positively impacted margins
• In addition, direct sales made up a larger percentage of overall sales
• Adjusted EBITDA increased by ~12% year over year due to scaling back operating expenses related to R&D and consolidating contract workers
• Despite the scale-back in R&D spending, the company intends to allocate funds on R&D necessary to incrementally advance current technologies, develop products and strengthen its marketing and sales efforts to capitalize on industry growth and market opportunities
• The company will continue to streamline operations by consolidating contract workers and negotiating for better payment terms
• Satisfied over $1.5mm in debt used to finance company operations
• The company successfully satisfied the majority of its convertible debt obligations, which will significantly reduce its yearly debt burden and minimize stock dilution
• The company has also settled additional debt in Q1 and will continue to optimize its capital structure to provide for business stability and growth
As of 4/18/2017, $35k of convertible debt is on the company's balance sheet
The MyDx ( MYDX
• mobile app reached over 50,000 downloads, up ~80% year over year, due to strong word of mouth and a growing social media presence
MyDx ( MYDX)
• App reached the #1 Ranking in the medical category in the Apple iOS app store, #1 for the keyword Cannabis, and is consistently in the Top 100 of FREE Apps.
• Brand Awareness is at an all-time high and continues to grow as the company's social media presence strengthens
• 85,000+ Twitter Followers
• 70,000+ Instagram Followers
• 40,000+ Facebook Followers
• With 40,000+ consumer-generated data points growing at over 100% year over year, the company is well positioned to capitalize on data-centric opportunities
• Data-licensing business model was implemented in the second half of 2016 to capitalize on the growing demand for data in the cannabis industry
• Insights the data has provided so far are currently being used to develop next generation smart technologies and consumer products
MyDx ( MYDX ) will continue to build out its sensory technology capabilities
CannaDx, the flagship brand in its portfolio, is seeing strong consumer demand
The company is still building brand awareness for its OrganaDx and AquaDx disposable sensors and intends to finish building-out those brands to capitalize on the growing demand for transparency in what consumers put into their bodies. These brands also diversify the company outside of the cannabis industry.
FY2016 EARNINGS CALL
A conference call with CEO Daniel Yazbeck and the investor community is scheduled as follows and the FY2016 Earnings Presentation will be available on or before Thursday, April 20, 2017 prior to the call.
Conference Call Details
(Press/ Media and the public are encouraged to participate)
Date & time: Thursday, April 20, 2017 at 10:00 a.m. (PDT)/ 1:00 p.m. (EDT)
https://join.onstreammedia.com/register/mydx/earningscall
Registration is required for access.
Please call in 5 minutes prior to the call, so that the call can begin promptly.
Agenda:
Business highlights and company performance, including record revenue & EBITDA growth
MyDx ( MYDX ) robust standing and performance relative to industry peers
The power of data and its transformative capabilities
The path forward to unlocking shareholder value and maximizing returns
Q&A
About MyDx, Inc. ( MYDX )
MyDx, Inc. ( MYDX ) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx ( MYDX )®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user's hand. The multi-use MyDx ( MYDX) analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx AquaDx®, OrganaDx™ and CannaDx™ sensors are now commercialized, and the AeroDx® application is next in line. All sensors will be compatible with a MyDx App that empowers consumers to live a healthier life by revealing the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com
Source: MyDx, Inc. ( MYDX )
I reported from the news from the email I received! See below if it's #1 now in the 20 min then great reporting on your behalf but I was not wrong in what I reported see below copy paste from email at received at 7:29 PST
The stocks below have been rated as today's best small cap stocks by MarketClub's Trade Triangle and Smart Scan technology. Use premium analysis on these stocks, or any of the symbols we cover with a 30-Day Trial.
Sponsor message:
# Symbol Description Open High Low Last Change % Vol Score Triangles
1. DBMM DIGITAL BRAND MEDIA & MARKETING GROUP 0.0012 0.0012 0.0009 0.0010 -0.0001 -9.09% 8,037,525 +100 Green Daily 0.000400 2017-03-22 Green Weekly 0.000500 2017-04-03 Green Monthly 0.000200 2016-12-01 entry signal
2. MYDX MYDX 0.0204 0.0217 0.0185 0.0197 +0.0019 +10.67% 44,448,334 +100 Green Daily 0.013500 2017-04-13 Green Weekly 0.002000 2017-03-10 Green Monthly 0.014350 2017-03-24 entry signal
3. RDAR RAADR 0.0012 0.0014 0.0010 0.0012 +0.0001 +9.09% 11,659,007 +100 Green Daily 0.000700 2017-04-17 Green Weekly 0.001000 2017-04-17 Green Monthly 0.000200 2016-11-08 entry signal
4. HHSE HANOVER HOUSE
0.01730 0.01900 0.01600 0.01830 +0.00165 +9.02% 4,303,312 +100 Green Daily 0.012400 2017-04-04 Green Weekly 0.012500 2017-04-05 Green Monthly 0.007100 2017-01-13 entry signal
5. CBIS CANNABIS SCIENCE INC 0.08075 0.08700 0.08050 0.08350 +0.00300 +3.73% 4,619,408 +100 Green Daily 0.076000 2017-04-13 Green Weekly 0.086500 2017-04-17 Green Monthly 0.020000 2016-03-24 entry signal
6. PNTV PLAYERS NETWORK INC 0.043500 0.045000 0.035000 0.041075 -0.002425 -5.57% 1,198,240 +90 Green Daily 0.030000 2017-03-29 Green Weekly 0.030000 2017-03-29 Green Monthly 0.002900 2016-01-06 entry signal
7. LBSR LIBERTY STAR URANIUM 0.0019 0.0020 0.0018 0.0019 +0.0001 +5.56% 1,318,365 +90 Green Daily 0.001700 2017-03-31 Green Weekly 0.001600 2017-01-11 Green Monthly 0.001900 2017-04-11 entry signal
8. SCON SUPERCONDUCTOR TECHNOLOGIES INC 2.1400 2.3800 2.0300 2.3624 +0.2624 +12.50% 1,489,579 +100 Green Daily 1.739000 2017-04-12 Green Weekly 1.350000 2017-03-21 Green Monthly 1.800000 2017-04-06 entry signal
9. NTEK NANOTECH ENTERTAINMENT INC 0.0446 0.0489 0.0420 0.0489 +0.0043 +9.64% 60,347 +100 Green Daily 0.050000 2017-04-07 Green Weekly 0.024000 2017-03-30 Green Monthly 0.030000 2017-04-05 entry signal
10. ADHC AMERICAN DIVERSIFIED 0.0023 0.0028 0.0022 0.0026 +0.0004 +17.39% 642,227 +90 Green Daily 0.002500 2017-03-27 Green Weekly 0.002700 2017-04-17 Green Monthly 0.000300 2017-01-10 entry signal
View Full List ...
Thousands of people, just like you, have made the jump from using our Top Penny Stocks list to MarketClub.
MarketClub can advance your trading with an entire set of online trading tools, not just the ability to create lists like this. Try MarketClub with a 30-Day Trial
Follow us on Facebook for updates throughout the trading day.
View all details and studies at http://club.ino.com/. Want more scans, instant alerts, and a custom portfolio? MarketClub has it all across all markets.
Thank you!
Thank you for subscribing to Today's Top Penny Stocks from INO.com
Market Club lists $MYDX as # 2 pick in Today's Top Penny Stocks for Tuesday, April 18th?
Great post makes perfect sense no panic here just need not look at the SP for a few days to take the drama out. Wish I had more gunpowder to buy more at this bargain price!
Analyst taking note!
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) Shares Building Momentum
By Michael Luke - April 6, 2017
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) shares more than doubled in a one month period recently. Now, if you’ve been following us, we talked about some catalysts in IMLFF that might have caused the stock to rise. There’s one major development that’s coming up soon, and it could be good news for companies.
If you haven’t heard about InMed Pharmaceuticals yet, it’s a pre-clinical biopharma company specializing in the development of therapies through research and development (R&D) into the extensive pharmacology of cannabinoids intertwined with innovative drug delivery systems. In the company’s own words, “InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.”
That said, INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) could be ripe for growth. If you haven’t been following the news, Canada has a legalization bill in the works for the legalization of cannabis, both for recreational and medicinal use, throughout the whole country. That in mind, this is a positive catalyst for the InMed Pharma, since it is based in Canada. Therefore, brands that already have an established presence in Canada, could benefit significantly from the potential legalization of marijuana.
If you haven’t been keeping up with InMed Pharmaceutical, it’s also had some positive company news. The company was featured in a Forbes article, “InMed Pharmaceuticals Is More Than Just Another Cannabis Drug Company“, which discussed the its innovative database, mapping out an array of cannabinoid combinations and a variety of diseases that they could possibly address.
The company is currently developing two drug candidates through preclinical testing and it’s targeting clinical programs for EB, a rare genetic skin disorder, and glaucoma. InMed’s management plans to begin EB clinical trials in 2018, and thereafter it is looking to begin trials with glaucoma and pain therapies. The company believes that the market for EB will exceed $1B per year. Additionally, the current market for glaucoma drugs is over $6B per year. That said, if InMed Properly executes, it could significantly drive the company’s revenues and earnings higher. In turn, this could potentially push the stock higher.
CFN Media Group, one of the leading creative agencies and digital media networks focused on legal cannabis, recently covered InMed Pharma and stated, “InMed Pharma has taken a more precise approach to the drug discovery process than most competitors via its bioinformatics platform. Using extensive databases and proprietary algorithms, the technology rapidly identifies cannabinoid combinations that are likely to have an effect on specific diseases. This helps them dramatically shorten the drug discovery period and increases the likelihood of success from the onset of drug development.
Once they’ve isolated promising cannabinoid compounds, the company isolates the genes responsible for producing them and injects the genes with bacteria that act as a factory for mass producing them in a process similar to the way insulin is manufactured. The company can then combine these various compounds to create unique therapies that target specific diseases without having to worry about costly extraction from entire cannabis plants.”
That in mind, InMed Pharmaceuticals is gaining some media coverage, which could increase brand awareness, and potentially drive more patients to the company, if and when it gains approval for its drug candidates. You might want to stay on top of company, as well as industry news because the stock could start moving again, with the cannabis legalization bill coming up soon. To stay on top of developments in IMLFF, you don’t have to be on your computer or tablet all day. You could subscribe to our free newsletter by simply entering your email address below, and only then we would email you on updates, if any, in the IMLFF.
Wow look at the tremendous volume almost even with 3mil 90 moving average. In my opinion I would say the PPS sell panic shake down is done nowhere to go now but up!
No Biggy- many company's do the same allot going on there. I would not panic we're only talking a ~2 week delay until April 15. If I had the additional funds I would look at this as the stock is on sale for limited time and would buy more even though I am underwater big time at this PPS
But look at the volume in trades very small amounts of sell. Guess they didn't get the news yet? Go figure!
Hmm interesting, note recent term agreement with RVVTF and IMLFF regarding treatments of kidney ailments)
RVVTF announces Phase 2 clinical study of REV-004 (Bucillamine) in cystinuria. (Kidney stones)
What happens to the stock today looking good for both I imagine.
Holding strong!
Article below
Revive Therapeutics Provides Corporate Update
BY MARKETWIRE - CANADA — 7:00 AM ET
TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Revive Therapeutics Ltd. (RVVTF) ("Revive" or the "Company") (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today provided a corporate update on its Phase 2 clinical study of REV-004 (Bucillamine) in cystinuria and warrant exercise.
Phase 2 Clinical Study of REV-004 (Bucillamine) in Cystinuria
The Company has engaged with five clinical sites to advance the Phase 2 study of REV-004 (Bucillamine) in cystinuria. The clinical sites participating in the Phase 2 study are: Massachusetts General Hospital, University of Wisconsin, University of Alabama, NYU School of Medicine, and Omega Medical Research. Investigational drug and lab kits have been delivered to clinical sites and the recruitment process of enrolling subjects to the Phase 2 study has begun. The Company will update on the progress of the study, including subject enrollment and clinical results, as they arise. Further information regarding the Phase 2 study can be found on the ClinicalTrials.gov website at the following website address: https://clinicaltrials.gov/ct2/show/NCT02942420.
Warrant Exercise
The Company is pleased to update that a total of 6,215,500 common share purchase warrants have been exercised at a price of $0.18 per common share. Proceeds from the exercise of these warrants totalled $1,118,790 and 6,215,500 common shares were issued from Revive's Treasury. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds raised are for general corporate purposes.
"I am pleased with the progress of the Phase 2 clinical study in cystinuria, the efforts in strengthening our strategy in building a novel cannabinoid-based pipeline, and the support we have received from our shareholders," said Craig Leon, Chief Executive Officer of Revive. "I look forward to updating the medical and investment community on the developments with the Phase 2 study in cystinuria, the cannabinoid-based pipeline activities, and the capital market activities as they arise."
As of March 28th, 2017 there are a total of 5,655,315 outstanding purchase warrants at $0.18 that expires on June 18, 2018. The Company currently has 53,893,567 common shares outstanding and 61,400,882 fully-diluted.
About Revive Therapeutics Ltd. (RVVTF)
Revive Therapeutics Ltd. (RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the joint venture with InMed Pharmaceuticals Inc. for development of cannabinoid-based therapies for targeting kidney diseases and entering into a definitive joint venture agreement; the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company's research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the inability to conclude a joint venture with InMed Pharmaceuticals Inc. on terms which are commercially reasonable or at all; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2016 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Neither the TSX-V nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT: Revive Therapeutics Ltd. (RVVTF) Craig Leon Chief Executive Officer (416) 272-5525 craig@revivethera.com www.revivethera.com Source: Revive Therapeutics Ltd. (RVVTF)
Revive Therapeutics Provides Corporate Update
BY MARKETWIRE - CANADA — 7:00 AM ET
TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Revive Therapeutics Ltd. (RVVTF) ("Revive" or the "Company") (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today provided a corporate update on its Phase 2 clinical study of REV-004 (Bucillamine) in cystinuria and warrant exercise.
Phase 2 Clinical Study of REV-004 (Bucillamine) in Cystinuria
The Company has engaged with five clinical sites to advance the Phase 2 study of REV-004 (Bucillamine) in cystinuria. The clinical sites participating in the Phase 2 study are: Massachusetts General Hospital, University of Wisconsin, University of Alabama, NYU School of Medicine, and Omega Medical Research. Investigational drug and lab kits have been delivered to clinical sites and the recruitment process of enrolling subjects to the Phase 2 study has begun. The Company will update on the progress of the study, including subject enrollment and clinical results, as they arise. Further information regarding the Phase 2 study can be found on the ClinicalTrials.gov website at the following website address: https://clinicaltrials.gov/ct2/show/NCT02942420.
Warrant Exercise
The Company is pleased to update that a total of 6,215,500 common share purchase warrants have been exercised at a price of $0.18 per common share. Proceeds from the exercise of these warrants totalled $1,118,790 and 6,215,500 common shares were issued from Revive's Treasury. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds raised are for general corporate purposes.
"I am pleased with the progress of the Phase 2 clinical study in cystinuria, the efforts in strengthening our strategy in building a novel cannabinoid-based pipeline, and the support we have received from our shareholders," said Craig Leon, Chief Executive Officer of Revive. "I look forward to updating the medical and investment community on the developments with the Phase 2 study in cystinuria, the cannabinoid-based pipeline activities, and the capital market activities as they arise."
As of March 28th, 2017 there are a total of 5,655,315 outstanding purchase warrants at $0.18 that expires on June 18, 2018. The Company currently has 53,893,567 common shares outstanding and 61,400,882 fully-diluted.
About Revive Therapeutics Ltd. (RVVTF)
Revive Therapeutics Ltd. (RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the joint venture with InMed Pharmaceuticals Inc. for development of cannabinoid-based therapies for targeting kidney diseases and entering into a definitive joint venture agreement; the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company's research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the inability to conclude a joint venture with InMed Pharmaceuticals Inc. on terms which are commercially reasonable or at all; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2016 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Neither the TSX-V nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT: Revive Therapeutics Ltd. (RVVTF) Craig Leon Chief Executive Officer (416) 272-5525 craig@revivethera.com www.revivethera.com Source: Revive Therapeutics Ltd. (RVVTF)
Just some speculation, but can you imagine the what the cross pollination of technologies between the companies $RVVTF, $IMLFF and an $OWCP could do with a couple of agreements. Dr. Friedman brings knowledge of what's going on in the Israel med MJ industry (OWCP) and RVVTF tied into $IMFF for biosynthesis WOW! I am holding my shares see what develops later on!
Dr Friedman is a leader in the field has just been hired by Revive. Specializes in liver. He has also been tied in with developments in OWCP as well which had an incredible run from pennies to $3 range last few weeks and are in production. This is looking very good for Revive to bring on such a power hitter! Given Inmed recent agreement with Revive (I.e. Addressing liver treatments) I can see some additional synergy here! Very exciting to see what comes next. I am just putting all the pieces together.
NEWS MARCH 22 OUT OF EUROPE ON INMED PHARMACEUTICAL FORBES ARTICLE REFERENCE
http://www.prnewswire.com/news-releases/skyrocketing-demand-for-high-quality-cannabis-concentrates-and-edibles-boosting-cannabis-cbd-oil-extraction-market-616812584.html
Great news day with all the info, could we break .35 PPS EOD? Ready for a ramp up. Better and more news out brings good visibility!
Imlff sorry